Multiple Sclerosis Drugs Market Size, Share, Growth, Analysis, 2034

Download Free Sample

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Multiple Sclerosis Drugs Market Size Analysis

Global Multiple Sclerosis Drugs Market Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Immunomodulators
  1. By Value
3. Immunosuppressants
  1. By Value
4. Interferons
  1. By Value
5. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectables
  1. By Value
  2. Intramuscular
    1. Intramuscular By Value
  3. Subcutaneous
    1. Subcutaneous By Value
  4. Intravenous
    1. Intravenous By Value
4. Infusions
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Stores
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Relapsing-remitting MS (RRMS)
  1. By Value
3. Primary-progressive MS (PPMS)
  1. By Value
4. Secondary-progressive MS (SPMS)
  1. By Value
5. Progressive-relapsing MS (PRMS)
  1. By Value

North America Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Immunomodulators
  1. By Value
3. Immunosuppressants
  1. By Value
4. Interferons
  1. By Value
5. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectables
  1. By Value
  2. Intramuscular
    1. Intramuscular By Value
  3. Subcutaneous
    1. Subcutaneous By Value
  4. Intravenous
    1. Intravenous By Value
4. Infusions
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Stores
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Relapsing-remitting MS (RRMS)
  1. By Value
3. Primary-progressive MS (PPMS)
  1. By Value
4. Secondary-progressive MS (SPMS)
  1. By Value
5. Progressive-relapsing MS (PRMS)
  1. By Value
U.S.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
2. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
    2. Intramuscular
      1. Intramuscular By Value
    3. Subcutaneous
      1. Subcutaneous By Value
    4. Intravenous
      1. Intravenous By Value
  4. Infusions
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
4. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Relapsing-remitting MS (RRMS)
    1. By Value
  3. Primary-progressive MS (PPMS)
    1. By Value
  4. Secondary-progressive MS (SPMS)
    1. By Value
  5. Progressive-relapsing MS (PRMS)
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Immunomodulators
  1. By Value
3. Immunosuppressants
  1. By Value
4. Interferons
  1. By Value
5. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectables
  1. By Value
  2. Intramuscular
    1. Intramuscular By Value
  3. Subcutaneous
    1. Subcutaneous By Value
  4. Intravenous
    1. Intravenous By Value
4. Infusions
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Stores
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Relapsing-remitting MS (RRMS)
  1. By Value
3. Primary-progressive MS (PPMS)
  1. By Value
4. Secondary-progressive MS (SPMS)
  1. By Value
5. Progressive-relapsing MS (PRMS)
  1. By Value
U.K.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
2. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
    2. Intramuscular
      1. Intramuscular By Value
    3. Subcutaneous
      1. Subcutaneous By Value
    4. Intravenous
      1. Intravenous By Value
  4. Infusions
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
4. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Relapsing-remitting MS (RRMS)
    1. By Value
  3. Primary-progressive MS (PPMS)
    1. By Value
  4. Secondary-progressive MS (SPMS)
    1. By Value
  5. Progressive-relapsing MS (PRMS)
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Immunomodulators
  1. By Value
3. Immunosuppressants
  1. By Value
4. Interferons
  1. By Value
5. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectables
  1. By Value
  2. Intramuscular
    1. Intramuscular By Value
  3. Subcutaneous
    1. Subcutaneous By Value
  4. Intravenous
    1. Intravenous By Value
4. Infusions
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Stores
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Relapsing-remitting MS (RRMS)
  1. By Value
3. Primary-progressive MS (PPMS)
  1. By Value
4. Secondary-progressive MS (SPMS)
  1. By Value
5. Progressive-relapsing MS (PRMS)
  1. By Value
China
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
2. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
    2. Intramuscular
      1. Intramuscular By Value
    3. Subcutaneous
      1. Subcutaneous By Value
    4. Intravenous
      1. Intravenous By Value
  4. Infusions
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
4. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Relapsing-remitting MS (RRMS)
    1. By Value
  3. Primary-progressive MS (PPMS)
    1. By Value
  4. Secondary-progressive MS (SPMS)
    1. By Value
  5. Progressive-relapsing MS (PRMS)
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Immunomodulators
  1. By Value
3. Immunosuppressants
  1. By Value
4. Interferons
  1. By Value
5. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectables
  1. By Value
  2. Intramuscular
    1. Intramuscular By Value
  3. Subcutaneous
    1. Subcutaneous By Value
  4. Intravenous
    1. Intravenous By Value
4. Infusions
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Stores
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Relapsing-remitting MS (RRMS)
  1. By Value
3. Primary-progressive MS (PPMS)
  1. By Value
4. Secondary-progressive MS (SPMS)
  1. By Value
5. Progressive-relapsing MS (PRMS)
  1. By Value
UAE
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
2. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
    2. Intramuscular
      1. Intramuscular By Value
    3. Subcutaneous
      1. Subcutaneous By Value
    4. Intravenous
      1. Intravenous By Value
  4. Infusions
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
4. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Relapsing-remitting MS (RRMS)
    1. By Value
  3. Primary-progressive MS (PPMS)
    1. By Value
  4. Secondary-progressive MS (SPMS)
    1. By Value
  5. Progressive-relapsing MS (PRMS)
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Immunomodulators
  1. By Value
3. Immunosuppressants
  1. By Value
4. Interferons
  1. By Value
5. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectables
  1. By Value
  2. Intramuscular
    1. Intramuscular By Value
  3. Subcutaneous
    1. Subcutaneous By Value
  4. Intravenous
    1. Intravenous By Value
4. Infusions
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Online Stores
  1. By Value
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Relapsing-remitting MS (RRMS)
  1. By Value
3. Primary-progressive MS (PPMS)
  1. By Value
4. Secondary-progressive MS (SPMS)
  1. By Value
5. Progressive-relapsing MS (PRMS)
  1. By Value
Brazil
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Immunomodulators
    1. By Value
  3. Immunosuppressants
    1. By Value
  4. Interferons
    1. By Value
  5. Others
    1. By Value
2. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectables
    1. By Value
    2. Intramuscular
      1. Intramuscular By Value
    3. Subcutaneous
      1. Subcutaneous By Value
    4. Intravenous
      1. Intravenous By Value
  4. Infusions
    1. By Value
3. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Online Stores
    1. By Value
4. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Relapsing-remitting MS (RRMS)
    1. By Value
  3. Primary-progressive MS (PPMS)
    1. By Value
  4. Secondary-progressive MS (SPMS)
    1. By Value
  5. Progressive-relapsing MS (PRMS)
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Multiple Sclerosis Drugs Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Pfizer
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Bayer AG
Teva Pharmaceutical Industries Ltd.
Novartis AG
Sanofi
F. Hoffmann-La Roche Ltd.
Celgene Corporation
Acorda Therapeutics Inc.
Biogen Inc.
Johnson & Johnson
EMD Serono
Eisai Co. Ltd.
Apitope
AbbVie Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

Get This Report

Our Clients:

Hindustan National Glass & Industries Limited

Table Of Content

Download Free Sample

Mitiksha Koul

Research Associate